Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Purpose Canadian Financial Income Series A T.BNC

The fund seeks to provide shareholders with (i) long-term capital appreciation through investment in a portfolio of Canadian Banks (defined below) (up to 70% on an equal weighted basis) and Canadian Insurance Companies (defined below) (up to 30% on an equal weighted basis) and (ii) monthly distributions.To achieve its investment objectives, the fund will invest primarily in equity securities of Canadian Banks (up to 70% on an equal weighted basis) and to a lesser extent Canadian Insurance Companies (up to 30% on an equal weighted basis). portfolio of Canadian Banks (defined below) (up to 70% on an equal weighted basis) and CanadianInsurance Companies (defined below) (up to 30% on an equal weighted basis) and (ii) monthlydistributions.


TSX:BNC - Post by User

Post by LittleLadyPhDon Aug 30, 2016 2:14pm
249 Views
Post# 25192042

I heard that the FDA wanted 2 more P3 trials...

I heard that the FDA wanted 2 more P3 trials...
One for papillary and one for CIS patients, each with a 5-7 year time frame. TST was unable to find anyone interested in investing in MCNA with this proviso from the FDA in place. In addition, Ipsen decided it was not rational for them to continue to develop MCNA in Europe/ROW. I heard this info from TST management in an email exchange the day after the 2 Aug PR after I contacted them to complain about the absolutely disappointing news. I see that many of you are holding onto hope that a second offer may emerge or that somehow someone will rescue MCNA from the shelf. My best guess is PLI might just be that company as they could potentially run those trials. However, in the meanwhile, other immunotherapeutic molecules are already in play for this indication from other companies and I'm afraid the window of opportunity for MCNA approval has closed. It is beyond awful for investors but IMHO even more so for NMIBC patients that this has happened. GLTA
<< Previous
Bullboard Posts
Next >>